Stuart Handelsman

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos et al. · Diabetes Care · 2022 · 199 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease

Zien Zhou, Meg Jardine, Qiang Li et al. · Stroke · 2021 · 118 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Rajiv Agarwal, Wanzhu Tu, Alfredo E. Farjat et al. · Annals of Internal Medicine · 2023 · 88 citations

Medicine, Pharmacology, Pharmacotherapy +17

Effect of metabolic alkalosis on respiratory function in patients with chronic obstructive lung disease.

Robert A. Bear, Marc B. Goldstein, Eliot A. Phillipson et al. · PubMed · 1977 · 56 citations

Life Sciences, Internal Medicine, Physiology +17

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

Ellen Burgess, Rajiv Agarwal, Stefan D. Anker et al. · Diabetes Care · 2022 · 35 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17